company background image
LAB

Genomma Lab Internacional. de BMV:LAB B Stock Report

Last Price

Mex$20.49

Market Cap

Mex$20.7b

7D

1.3%

1Y

-0.4%

Updated

29 Jun, 2022

Data

Company Financials +
LAB B fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends2/6

LAB B Stock Overview

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally.

Genomma Lab Internacional. de Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genomma Lab Internacional. de
Historical stock prices
Current Share PriceMex$20.49
52 Week HighMex$23.00
52 Week LowMex$16.80
Beta0.48
1 Month Change2.30%
3 Month Change-6.22%
1 Year Change-0.39%
3 Year Change16.42%
5 Year Change-12.29%
Change since IPO150.18%

Recent News & Updates

Shareholder Returns

LAB BMX PharmaceuticalsMX Market
7D1.3%-1.5%1.7%
1Y-0.4%3.3%1.3%

Return vs Industry: LAB B underperformed the MX Pharmaceuticals industry which returned 5.6% over the past year.

Return vs Market: LAB B underperformed the MX Market which returned 1.6% over the past year.

Price Volatility

Is LAB B's price volatile compared to industry and market?
LAB B volatility
LAB B Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement7.1%
Market Average Movement4.6%
10% most volatile stocks in MX Market7.9%
10% least volatile stocks in MX Market2.7%

Stable Share Price: LAB B is not significantly more volatile than the rest of MX stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: LAB B's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19962,365Jorge Luis Brake Valderramahttps://www.genommalab.com

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands.

Genomma Lab Internacional. de Fundamentals Summary

How do Genomma Lab Internacional. de's earnings and revenue compare to its market cap?
LAB B fundamental statistics
Market CapMex$20.75b
Earnings (TTM)Mex$1.47b
Revenue (TTM)Mex$15.93b

14.1x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LAB B income statement (TTM)
RevenueMex$15.93b
Cost of RevenueMex$6.05b
Gross ProfitMex$9.88b
Other ExpensesMex$8.41b
EarningsMex$1.47b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)1.46
Gross Margin62.04%
Net Profit Margin9.23%
Debt/Equity Ratio52.1%

How did LAB B perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

26%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is LAB B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LAB B?

Other financial metrics that can be useful for relative valuation.

LAB B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA7.4x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does LAB B's PE Ratio compare to its peers?

LAB B PE Ratio vs Peers
The above table shows the PE ratio for LAB B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average52.4x
600285 Henan Lingrui Pharmaceutical
17.9x17.7%CN¥7.0b
3933 United Laboratories International Holdings
7.3x7.4%HK$8.2b
SOT Societe de Therapeutique Marocaine
41.3xn/aد.م10.3b
603718 Shanghai Hile Bio-Technology
144.9xn/aCN¥7.3b
LAB B Genomma Lab Internacional. de
14.1x17.9%Mex$20.7b

Price-To-Earnings vs Peers: LAB B is good value based on its Price-To-Earnings Ratio (14.1x) compared to the peer average (52.4x).


Price to Earnings Ratio vs Industry

How does LAB B's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

Price-To-Earnings vs Industry: LAB B is good value based on its Price-To-Earnings Ratio (14.1x) compared to the Global Pharmaceuticals industry average (21.9x)


Price to Earnings Ratio vs Fair Ratio

What is LAB B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LAB B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LAB B's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of LAB B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LAB B (MX$20.49) is trading below our estimate of fair value (MX$52.09)

Significantly Below Fair Value: LAB B is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: LAB B is good value based on its PEG Ratio (0.8x)


Discover undervalued companies

Future Growth

How is Genomma Lab Internacional. de forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


17.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LAB B's forecast earnings growth (17.9% per year) is above the savings rate (7.1%).

Earnings vs Market: LAB B's earnings (17.9% per year) are forecast to grow faster than the MX market (9.9% per year).

High Growth Earnings: LAB B's earnings are forecast to grow, but not significantly.

Revenue vs Market: LAB B's revenue (8.7% per year) is forecast to grow faster than the MX market (6.2% per year).

High Growth Revenue: LAB B's revenue (8.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LAB B's Return on Equity is forecast to be low in 3 years time (19.3%).


Discover growth companies

Past Performance

How has Genomma Lab Internacional. de performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


16.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LAB B has high quality earnings.

Growing Profit Margin: LAB B's current net profit margins (9.2%) are lower than last year (10.1%).


Past Earnings Growth Analysis

Earnings Trend: LAB B has become profitable over the past 5 years, growing earnings by 16.3% per year.

Accelerating Growth: LAB B's earnings growth over the past year (3.9%) is below its 5-year average (16.3% per year).

Earnings vs Industry: LAB B earnings growth over the past year (3.9%) underperformed the Pharmaceuticals industry 10.8%.


Return on Equity

High ROE: LAB B's Return on Equity (14.2%) is considered low.


Discover strong past performing companies

Financial Health

How is Genomma Lab Internacional. de's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: LAB B's short term assets (MX$12.1B) exceed its short term liabilities (MX$7.0B).

Long Term Liabilities: LAB B's short term assets (MX$12.1B) exceed its long term liabilities (MX$4.8B).


Debt to Equity History and Analysis

Debt Level: LAB B's net debt to equity ratio (37.2%) is considered satisfactory.

Reducing Debt: LAB B's debt to equity ratio has reduced from 84.3% to 52.1% over the past 5 years.

Debt Coverage: LAB B's debt is well covered by operating cash flow (42.6%).

Interest Coverage: LAB B's interest payments on its debt are well covered by EBIT (8x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Genomma Lab Internacional. de current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.86%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: LAB B's dividend (1.86%) isn’t notable compared to the bottom 25% of dividend payers in the MX market (1.91%).

High Dividend: LAB B's dividend (1.86%) is low compared to the top 25% of dividend payers in the MX market (5.99%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether LAB B's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if LAB B's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (26.1%), LAB B's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (22%), LAB B's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Jorge Luis Brake Valderrama

3.75yrs

Tenure

Mr. Jorge Luis Brake Valderrama is the Chief Executive Officer at Genomma Lab Internacional SAB de CV since September 10, 2018. He held the position of Senior Vice President of Global Operations at Laureat...


Leadership Team

Experienced Management: LAB B's management team is considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genomma Lab Internacional, S.A.B. de C.V.'s employee growth, exchange listings and data sources


Key Information

  • Name: Genomma Lab Internacional, S.A.B. de C.V.
  • Ticker: LAB B
  • Exchange: BMV
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: Mex$20.746b
  • Shares outstanding: 1.01b
  • Website: https://www.genommalab.com

Number of Employees


Location

  • Genomma Lab Internacional, S.A.B. de C.V.
  • Av. Antonio Dovalí Jaime no.70
  • Torre C, Piso 2, Despacho A
  • Mexico City
  • Distrito Federal
  • 1210
  • Mexico

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.